Prices delayed ≤15 min
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimen
Frequently Asked Questions about PFE
What does Pfizer Inc. (PFE) do?
Pfizer Inc. is a global leader in the biopharmaceutical industry, focusing on the discovery, development, manufacturing, marketing, and distribution of medicines and vaccines. The company offers a diverse range of products across various therapeutic areas, including cardiovascular, metabolic, and women's health, with well-known brands like Premarin and Eliquis.
Is PFE stock a good investment in 2026?
While Pfizer Inc. has faced a slight revenue decline of 1.6%, it still boasts a significant revenue figure of $62.58 billion. Investors should consider the company's strong free cash flow of $9.08 billion, which could support future growth and stability, making it a potentially attractive investment in the long term.
What is Pfizer Inc.'s market capitalisation and stock price?
As of now, Pfizer Inc. has a market capitalization of approximately $145.61 billion, with its stock currently priced at $25.61. This positions the stock within a 52-week high of $27.69 and a low of $20.92, reflecting some volatility in the market.
Does PFE pay dividends to shareholders?
Pfizer Inc. does not currently pay dividends to its shareholders. Instead, the company appears to be focusing on reinvesting its earnings to support growth and innovation in its biopharmaceutical offerings.
How profitable is Pfizer Inc.?
Pfizer Inc. reported a net income of $7.77 billion, resulting in a net margin of 12.4%. The company also generates a robust free cash flow of $9.08 billion, indicating strong profitability despite the absence of available ROE data.
What is PFE's P/E ratio and is the stock overvalued?
Pfizer Inc. does not have a P/E ratio available, which makes traditional valuation comparisons challenging. Given the current market dynamics in the healthcare sector, investors should evaluate PFE in the context of its revenue and free cash flow rather than relying solely on P/E metrics.
How much debt does Pfizer Inc. have?
Pfizer Inc. does not disclose a debt-to-equity ratio, suggesting that detailed debt information is not available. However, with a current ratio of 1.16, the company appears to maintain a healthy balance sheet, indicating it can cover its short-term liabilities.
What is PFE's 52-week trading range?
Pfizer Inc. has seen a trading range between $20.92 and $27.69 over the past 52 weeks. Currently, the stock is priced at $25.61, which is closer to its 50-day moving average of $25.31 and significantly above its 200-day moving average of $24.47.
Is PFE a growth stock or value stock?
With a revenue growth rate of -1.6% and no available EPS data, Pfizer Inc. might not fit the typical profile of a growth stock. Instead, it leans more towards being a value stock, particularly given its substantial free cash flow and established market presence.
What are the main risks of investing in PFE?
Investing in Pfizer Inc. carries several risks, including its low beta of 0.41, which indicates less volatility compared to the market. Additionally, the company operates in a highly competitive healthcare sector, where innovation and regulatory challenges could impact its market position.